[1] 孙惠川,王征,周俭,等.2017年版中国肝癌诊断和治疗规范解读.实用肿瘤杂志,2018,33:1-3.
[2] Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 2013, 31: 3501-3508.
[3] Cheng AL,Kang YK,Lin DY,et al. Sunitinib versus sorafenib in advanced hepatocelluar cancer: results of a randomized phase Ⅲ trial.J Clin Oncol,2013,31:4067-4075.
[4] Peng S, Li JY, Zhao YY, et al. Sa1860 Apatinib inhibited cell proliferation directly through suppressing VEGF signaling in extrahepatic bile duct carcinoma. Gastroenterology,2015,148:1026-1027.
[5] Giandomenico Roviello,Andrea Ravelli,Karol Polom,et al.Apatinib:A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.Cancer Letters,2016,2:187-191.
[6] Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. J Clin Oncol,2014,32:4019.
[7] Horsley L,Marti K,Jayson GC.Is the toxicity of anti-angiogenie drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol, 2012, 8: 283-293. |
